High rate of hepatitis B reactivation during tyrosine kinase inhibitor treatment among patients with chronic myeloid leukemia in Korea.

Abstract

Median age (yr) 52 (20–91) Sex male (N, %) 1,386 (60.8) Median duration of TKI treatment, months (range) 51.3 (1–160.5) TKI Imatinib, N (%) 1,563 (68.6) Dasatinib, N (%) 825 (36.2) Nilotinib, N (%) 678 (29.8) Radotinib, N (%) 154 (6.8) N of TKIs 1 TKI, N (%) 1,552 (68.1) 2 TKIs, N (%) 533 (23.4) 3 TKIs, N(%) 171 (7.5) 4 TKIs, N (%) 22 (1.0) HBV infection, N (%) 143 (6.3) HBV reactivation, N (% of HBV carrier) 33 (23.1) During imatinib, N 24 During dasatinib, N 6 During nilotinib, N 1 During radotinib, N 0 HBV reactivation events/1,000 patients-year Imatinib, events/1,000 patients-year 3.5 Dasatinib, events/1,000 patients-year 3.0 Nilotinib, events/1,000 patients-year 0.6 Radotinib, events/1,000 patients-year 0 Median interval (mo) from TKI initiation to HBV reactivation, (range) 2 (0–67) Death, N (%) 466 (20.5)